Safety and efficacy of azacitidine in myelodysplastic syndromes

被引：25
|
作者：
Vigil, Carlos E. [1 ]
Martin-Santos, Taida [1 ]
Garcia-Manero, Guillermo [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2010年 / 4卷
关键词：
Azacitidine; MDS; hypomethylating agents; MYELOID-LEUKEMIA; VALPROIC ACID; 5-AZACYTIDINE; TRANSPLANTATION; EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; METHYLATION; COMBINATION; ANTIGENS; CANCER;
D O I：
10.2147/DDDT.S3143
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.
引用
收藏
页码：221 / 229
页数：9
相关论文
共 50 条
  • [41] 5′-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3
    M Breccia
    L Cannella
    M Santopietro
    G Loglisci
    V Federico
    A Salaroli
    M Nanni
    M Mancini
    G Alimena
    Leukemia, 2011, 25 : 736 - 737
  • [42] Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
    Garcia-Delgado, Regina
    de Miguel, Dunia
    Bailen, Alicia
    Ramon Gonzalez, Jose
    Bargay, Joan
    Falantes, Jose F.
    Andreu, Rafael
    Fernando, Ramosh
    Tormo, Mar
    Brunet, Salut
    Figueredo, Antonio
    Casano, Javier
    Medina, Angeles
    Badiella, Llorenc
    Fernandez Jurado, Antonio
    Sanz, Guillermo
    LEUKEMIA RESEARCH, 2014, 38 (07) : 744 - 750
  • [43] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    A G Dinmohamed
    Y van Norden
    A A van de Loosdrecht
    M Jongen-Lavrencic
    Leukemia, 2016, 30 : 1795 - 1796
  • [44] Which myelodysplastic syndromes patients are candidates for treatment with azacitidine?
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2007, 31 : S20 - S20
  • [45] Impact of Two Azacitidine Administration Schedules in Myelodysplastic Syndromes
    Sapinho, Guilherme
    Alves-Ribeiro, Lidia
    Infante, Joana
    Kalim, Sahir
    Lacerda, Joao
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S309 - S309
  • [46] SAFETY PROFILE OF AZACITIDINE IN THE TREATMENT OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKAEMIA
    Minoia, C.
    Sgherza, N.
    Greco, G.
    Buquicchio, C.
    Loseto, G.
    de Fazio, V.
    Iacobazzi, A.
    Rana, A.
    Merchionne, F.
    Tarantini, G.
    Pavone, V.
    Guarini, A.
    HAEMATOLOGICA, 2014, 99 : 619 - 619
  • [47] Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia
    Lesley J. Scott
    Drugs, 2016, 76 : 889 - 900
  • [48] PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Zeidan, A. M.
    Garcia, J.
    Fenaux, P.
    Platzbecker, U.
    Miyazaki, Y.
    Xiao, Z.
    Zhou, Y.
    Naqvi, K.
    Kye, S.
    Manero, G. Garcia
    LEUKEMIA RESEARCH, 2021, 108 : S47 - S47
  • [49] Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Kambhampati, Suman
    Scott, Bart L.
    Tefferi, Ayalew
    Cogle, Christopher R.
    Edenfield, William
    Hetzer, Joel
    Kumar, Keshava
    Skikne, Barry S.
    BLOOD, 2012, 120 (21)
  • [50] Limited efficacy of azacitidine, with or without erythropoietin, in low-risk myelodysplastic syndromes resistant to erythropoietin
    Eclache, Virginie
    HEMATOLOGIE, 2016, 22 (05): : 308 - +
12345